SG11201803813UA - 1,3,4-thiadiazole compounds and their use in treating cancer - Google Patents
1,3,4-thiadiazole compounds and their use in treating cancerInfo
- Publication number
- SG11201803813UA SG11201803813UA SG11201803813UA SG11201803813UA SG11201803813UA SG 11201803813U A SG11201803813U A SG 11201803813UA SG 11201803813U A SG11201803813U A SG 11201803813UA SG 11201803813U A SG11201803813U A SG 11201803813UA SG 11201803813U A SG11201803813U A SG 11201803813UA
- Authority
- SG
- Singapore
- Prior art keywords
- cambridge
- international
- astrazeneca
- building
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Title: 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER (I) (57) : A compound of Foiinula (I) or a pharmaceutically acceptable salt thereof, where: Q can be 5-methylpyridazin-3-yl, 5- chloropyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-y1; R can be hydrogen, fluoro, or methoxy; R 1 can be hydro- gen, methoxy, difluoromethoxy, or trifluoromethoxy; and R 2 can be methyl or ethyl. The compound of formula (I) can inhibit glutaminase, e.g., GLS1. (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 111111111M 1111111111111111111111111111111111111111111 11111111111111R111111111111111 (10) International Publication Number WO 2017/093300 Al WIPO I PCT (43) International Publication Date 8 June 2017 (08.06.2017) (74) Agent: COOK, Andrew; AstraZeneca Intellectual Prop- erty Mereside, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art 21(3)) (51) International Patent Classification: C07D 417/14 (2006.01) A61K 31/53 (2006.01) A61K 31/501 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2016/079251 (22) International Filing Date: 30 November 2016 (30.11.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/260787 30 November 2015 (30.11.2015) US (71) Applicants: ASTRAZENECA AB [SE/SE]; SE-151 85 Sodertalje (SE). CANCER RESEARCH TECHNO- LOGY LIMITED [GB/GB]; Angel Building 407 St John Street, London EC1V 4AD (GB). (72) Inventors: FINLAY, Maurice, Raymond, Verschoyle; AstraZeneca R&D Cambridge, Darwin Building Cam- bridge Science Park, Milton Road, Cambridge Cambridge- shire CB4 OFZ (GB). NISSINK, Johannes, Wilhelmus, Maria; AstraZeneca, Darwin Building Cambridge Science Park, Milton Road, Cambridge Canbridgeshire CB4 OWG (GB). CHARLES, Mark, David; CRT Discovery Laborat- ories, Jonas Webb Building, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). WOOD, Matt; AstraZeneca UG22 Redesmere Silk Road Business Park, Charter way, Macclesfield Cheshire SK10 2NX (GB). W O 20 17 /093300 Al
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562260787P | 2015-11-30 | 2015-11-30 | |
PCT/EP2016/079251 WO2017093300A1 (en) | 2015-11-30 | 2016-11-30 | 1,3,4-thiadiazole compounds and their use in treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201803813UA true SG11201803813UA (en) | 2018-06-28 |
Family
ID=57421876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201803813UA SG11201803813UA (en) | 2015-11-30 | 2016-11-30 | 1,3,4-thiadiazole compounds and their use in treating cancer |
Country Status (25)
Country | Link |
---|---|
US (1) | US9938265B2 (en) |
EP (1) | EP3383871B1 (en) |
JP (1) | JP6873132B2 (en) |
KR (1) | KR20180083412A (en) |
CN (1) | CN108349967B (en) |
AR (1) | AR106876A1 (en) |
AU (1) | AU2016363719B2 (en) |
BR (1) | BR112018010812A2 (en) |
CA (1) | CA3005516C (en) |
CL (1) | CL2018001408A1 (en) |
CO (1) | CO2018006929A2 (en) |
DK (1) | DK3383871T3 (en) |
DO (1) | DOP2018000134A (en) |
EA (1) | EA201891240A1 (en) |
ES (1) | ES2759940T3 (en) |
IL (1) | IL258644A (en) |
MX (1) | MX2018006528A (en) |
NI (1) | NI201800065A (en) |
PE (1) | PE20181450A1 (en) |
PH (1) | PH12018501132A1 (en) |
SG (1) | SG11201803813UA (en) |
SV (1) | SV2018005701A (en) |
TN (1) | TN2018000126A1 (en) |
TW (1) | TW201730188A (en) |
WO (1) | WO2017093300A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
TW201733587A (en) | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-thiadiazole compounds and their use in treating cancer |
WO2020078350A1 (en) * | 2018-10-16 | 2020-04-23 | 南京明德新药研发有限公司 | Thiadiazole derivative and uses thereof as a gls1 inhibitor |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE377011T1 (en) * | 1999-11-24 | 2007-11-15 | Merck & Co Inc | GAMMA-HYDROXY-2-(FLUORALKYLAMINOCARBONYL)-1-PIPERAZINE PENTANAMIDE AS AN HIV PROTEASE INHIBITOR |
US6451828B1 (en) * | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
TWI287010B (en) * | 2003-06-12 | 2007-09-21 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
US8003806B2 (en) * | 2004-11-12 | 2011-08-23 | OSI Pharmaceuticals, LLC | Integrin antagonists useful as anticancer agents |
MA33224B1 (en) * | 2009-04-20 | 2012-04-02 | Hoffmann La Roche | Proline derivatives as catecin inhibitors |
ES2761866T3 (en) * | 2011-11-21 | 2020-05-21 | Calithera Biosciences Inc | Heterocyclic glutaminase inhibitors |
DK2920168T3 (en) * | 2012-11-16 | 2021-10-18 | Calithera Biosciences Inc | HETEROCYCLIC GLUTAMINASE INHIBITORS |
US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
JP6783663B2 (en) * | 2014-01-06 | 2020-11-11 | ライゼン・ファーマシューティカルズ・エスアー | New glutaminase inhibitor |
US20150258082A1 (en) * | 2014-03-14 | 2015-09-17 | Francesco Parlati | Combination therapy with glutaminase inhibitors |
GB201409624D0 (en) | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
TW201733587A (en) | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-thiadiazole compounds and their use in treating cancer |
TW201731511A (en) | 2015-11-30 | 2017-09-16 | 阿斯特捷利康公司 | 1,3,4-thiadiazole compounds and their use in treating cancer |
-
2016
- 2016-11-29 TW TW105139312A patent/TW201730188A/en unknown
- 2016-11-29 US US15/363,018 patent/US9938265B2/en active Active
- 2016-11-30 CN CN201680067261.2A patent/CN108349967B/en active Active
- 2016-11-30 AR ARP160103665A patent/AR106876A1/en unknown
- 2016-11-30 BR BR112018010812A patent/BR112018010812A2/en not_active Application Discontinuation
- 2016-11-30 MX MX2018006528A patent/MX2018006528A/en unknown
- 2016-11-30 PE PE2018001021A patent/PE20181450A1/en unknown
- 2016-11-30 KR KR1020187017164A patent/KR20180083412A/en unknown
- 2016-11-30 JP JP2018526717A patent/JP6873132B2/en active Active
- 2016-11-30 TN TNP/2018/000126A patent/TN2018000126A1/en unknown
- 2016-11-30 WO PCT/EP2016/079251 patent/WO2017093300A1/en active Application Filing
- 2016-11-30 AU AU2016363719A patent/AU2016363719B2/en active Active
- 2016-11-30 SG SG11201803813UA patent/SG11201803813UA/en unknown
- 2016-11-30 DK DK16802102.0T patent/DK3383871T3/en active
- 2016-11-30 CA CA3005516A patent/CA3005516C/en active Active
- 2016-11-30 EA EA201891240A patent/EA201891240A1/en unknown
- 2016-11-30 EP EP16802102.0A patent/EP3383871B1/en active Active
- 2016-11-30 ES ES16802102T patent/ES2759940T3/en active Active
-
2018
- 2018-04-11 IL IL258644A patent/IL258644A/en unknown
- 2018-05-24 CL CL2018001408A patent/CL2018001408A1/en unknown
- 2018-05-29 SV SV2018005701A patent/SV2018005701A/en unknown
- 2018-05-29 NI NI201800065A patent/NI201800065A/en unknown
- 2018-05-29 PH PH12018501132A patent/PH12018501132A1/en unknown
- 2018-05-29 DO DO2018000134A patent/DOP2018000134A/en unknown
- 2018-06-29 CO CONC2018/0006929A patent/CO2018006929A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN108349967B (en) | 2022-02-15 |
CA3005516A1 (en) | 2017-06-08 |
EA201891240A1 (en) | 2018-11-30 |
EP3383871A1 (en) | 2018-10-10 |
DK3383871T3 (en) | 2019-12-16 |
CN108349967A (en) | 2018-07-31 |
AU2016363719A1 (en) | 2018-07-05 |
EP3383871B1 (en) | 2019-09-11 |
KR20180083412A (en) | 2018-07-20 |
US20170152254A1 (en) | 2017-06-01 |
IL258644A (en) | 2018-06-28 |
CL2018001408A1 (en) | 2018-10-12 |
BR112018010812A2 (en) | 2018-11-27 |
NI201800065A (en) | 2018-10-18 |
SV2018005701A (en) | 2018-11-27 |
PE20181450A1 (en) | 2018-09-12 |
JP6873132B2 (en) | 2021-05-19 |
US9938265B2 (en) | 2018-04-10 |
WO2017093300A1 (en) | 2017-06-08 |
AU2016363719A8 (en) | 2018-07-12 |
MX2018006528A (en) | 2019-05-15 |
AU2016363719B2 (en) | 2019-11-14 |
JP2019501134A (en) | 2019-01-17 |
CA3005516C (en) | 2024-04-16 |
TN2018000126A1 (en) | 2019-10-04 |
ES2759940T8 (en) | 2020-05-20 |
DOP2018000134A (en) | 2018-06-30 |
CO2018006929A2 (en) | 2018-10-10 |
ES2759940T3 (en) | 2020-05-12 |
TW201730188A (en) | 2017-09-01 |
AR106876A1 (en) | 2018-02-28 |
PH12018501132A1 (en) | 2019-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201804915RA (en) | Methods for treating huntington's disease | |
SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
SG11201804934PA (en) | Novel Compounds | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201808108XA (en) | Synthesis of indazoles | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
SG11201810352XA (en) | New antibacterial compounds | |
SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
SG11201803810XA (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |